Portable NMR & MRI Machines for Industrial and Healthcare Applications
Disclaimers

Information contained in this document has been prepared by Nanalysis Scientific Corp. ("Nanalysis" or the "Company") and contains information pertaining to the business, operations, and assets of the Company. The information contained in this document (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in Nanalysis, and (c) is not a recommendation to invest in the Company. Securities are speculative and involve risks that should be considered. Prospective investors should conduct their own analysis and investigation of securities and consult with their own financial, legal, tax, and other business advisors before investing. The information presented herein was prepared or obtained by Nanalysis. Nothing contained herein should be relied on as a promise or representation of the future performance of the Company. All financial numbers are as of Sep. 30, 2019 except as otherwise stated.

FORWARD-LOOKING STATEMENTS: In the interests of providing Nanalysis shareholders and potential investors with information regarding the Company, including management’s assessment of future plans and operations. This document contains “forward-looking statements” as defined by applicable securities legislation. The use of any words such as "anticipate", "continue", "estimate", "expect", "may", and similar expressions are intended to identify forward-looking statements. Forward-looking statements are often, but not always, identified by such words. These statements involve known and unknown risks, assumptions, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such statements. Forward-looking statements in this document include but are not limited to statements and tables with respect to: Future growth of the Company’s business, the ability to graduate to the TSX and pay dividends, the Company’s acquisition strategy, the ability to develop future products, and the possible associated results. The Company’s actual performance and financial results in the future could differ materially from any estimates or projections of future performance implied by the forward-looking statements.

For additional information, please refer to the Corporation’s public filings available on SEDAR at www.sedar.com. All forward-looking statements contained in this document are expressly qualified by this cautionary statement.
Nanalysis Scientific Corp.

A market-leading and category-creating global technology company.

Nanalysis develops **magnetic resonance imaging and spectrometer** hardware and software products, for industrial and healthcare customers.

Technology is patent protected, and products are manufactured in our own domestic facility using proprietary manufacturing processes, which constitute a material competitive barrier to entry.

### Cap Table and Financial Metrics*

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHARE PRICE</td>
<td>$1.20</td>
</tr>
<tr>
<td>COMMON SHARES OUTSTANDING (approximate)</td>
<td>94M</td>
</tr>
<tr>
<td>BASIC MARKET CAP (approximate)</td>
<td>$110M</td>
</tr>
<tr>
<td>Revenue TTM (approximate)</td>
<td>$16M</td>
</tr>
<tr>
<td>EBITDA TTM (estimate)</td>
<td>$1.9M</td>
</tr>
<tr>
<td>Cash (including Quad Systems)</td>
<td>$15M</td>
</tr>
</tbody>
</table>

* Canadian dollars

---

**Sean Krakiwsky**  
CEO & Founder  
- B.Sc. & M.Sc., Electrical Engineering from U. of Calgary  
- 20 years of tech. start-up experience (incl. Acceleware TSXV: AXE)

**Luke Caplette**  
CFO  
- CPA, CA  
- 12 Years of Finance, M&A Experience

**Julien Muller**  
CTO  
- B.Sc. in Electrical Engineering, U of Strasbourg  
- 16 years of MR tech experience
Reasons to Buy

Portable Magnetic Resonance intellectual property

• Revolutionary technology category: Portable NMR & MRI for Industry & Healthcare

Established product line bolstered by recent acquisition

• Most of our revenue is derived from magnetic resonance for industrial applications, not human medical imaging
• Building strong business foundation on industrial analysis, and incubating medical imaging group

100% Year-Over-Year Growth Trajectory*

• Sell Direct in USA, Canada, Germany, Switzerland, France. Network of 45 dealers in the rest of world

Our Vision & Mission

To disrupt the MRI space, providing accessibility for anyone, at any time, as part of society’s next gen personalized prevention-centric healthcare system.

Miniaturizing & democratizing magnetic resonance.

*As shown in Sept 30, 2021 ended Interim Condensed Financial Statements
Magnetic Resonance

**Nuclear Magnetic Resonance Imaging - MRI**
- Medical imaging technique
- For use in healthcare industries
- Imaging in industry applications
- Early stages of exploiting promise of MRI to not just create quality images, but analyze cells

**Nuclear Magnetic Resonance Spectroscopy - NMR**
- Important tool in chemical analysis. An
- For use in pharmaceuticals / biotech, cannabis, nutraceuticals, oil & gas, mining, forensics and education industries.
- “Monopoly” by Bruker globally (except for Japan)

---

**Incumbent/Old: High Field Magnetic Resonance**
Gold Standard of Analysis & Imaging

- Expensive
- Unsafe
- Liquid Helium
- Gatekeeper
- Huge/heavy

**New:**

- Affordable
- Easy to use
- No cryogens
- Point of need
- Portable

---

✓ Miniaturization & Democratization of standard will drive adoption and expand market
Current Products: 60% Gross Margins

Benchtop Products

- **60 MHz**
  - US $45K-70K since 2013
  - R&D labs, QA/QC

- **100 MHz**
  - US $125K-155K since 2019

High Field NMR

- **Pulse Console**
  - US $115K since 2020
  - Better performance

- **MRI Console**
  - US $45K since 2020
  - High-performance, affordable, easy-to-use modular alternative

MRI

- **Hyperpolarization**
  - US $45K since 2020
  - Sensitivity enhancement

Software

- **OneTouch™**

Accessories

- **Flow Kit**
  - US $7K since 2015

- **Auto sampler**
  - US $13K since 2018

Installation & Maintenance on Nanalysis and 3rd Party Equipment
Milestones & Catalysts

Formally Incorporated 2009

- Alpha prototypes
- Established Mfg, Facility & Direct Sales
- 1st Patent granted
- Launched first product: NMReady-60e
- Launched second product: NMReady-60PRO
- Rejected takeover bid by large Nasdaq listed company
- Announced 100 MHz Product
- 2nd Acquisition One Moon Scientific
- 3rd Acq. KPrime
- 4th Acq. Quad Sys.

Founding

Pre-Revenue Product Dev 2014

- Initial Sales & Manufacturing
- RTO & $6.5M Financing
- 1st Acquisition RS2D
- $11M Financing
- $15M Financing

Initial Sales & Manufacturing 2018

- Achieve Profitability
- 100% Annual Revenue growth
- 500+ employees
- $150M+ in revenue
- $30M+ in profit
- Trading on major stock exchange - Nasdaq

Our Next Decade Will Be Better Than Our First Decade!

- Q1 2022
  - Large service contracts
  - Target of $35 million in revenue
  - Further analyst coverage
- 2022
- 2025
Intellectual Property

Patents on main technical challenges of miniaturizing & high throughput NMR
- Patents granted in United States, and other jurisdictions such as China and Japan
- Patents protect key barriers to main technical challenge of compact NMR system development
- Additional patent applications ongoing in support of growing product line

Proprietary electronics, firmware, software, enclosure
- Custom boards designed and assembled in the Calgary manufacturing plant
- Firmware and software developed by in-house specialists

Proprietary manufacturing processes
- Specialized techniques and algorithms make our products very difficult to reverse engineer

Maintaining thermally stable magnetic fields to 9 decimal places of uniformity in all three vectors <x, y, z> is hard... Nanalysis is a global leader in the space!

US Patent Office Numbers:
- US 8,712,706 B2
- US 9,341,690 B2
- US 9,952,294 B2

More patents pending
Growth Strategy

Baseline Business, Product Innovation
- Numerous large-scale industrial applications
- Academic teaching, research labs, and industry
- New, best-in-class product launched recently
- Ruggedized product targeting industrial manufacturing customers

Industry Partnerships
- **Bosch** – Shipping vessel fuel analyzer
  - Total possible market size of 110k units
- **German Police** – Mobile police labs
  - Total annual global spend by major security forces in the billions for analytical instrumentation

Lead with Service in Some Verticals
- **Security** - $160M contract win in 2022
  - Global market is US$12B/y and expected to be US$30B/y by 2030

NMR → MRI
- Future MRI products and applications
- Machine Learning, AI, and Cloud
- FDA approved human MRI product
‘Appification’ through Software: Key Growth Driver

Traditional MR Output

Complex, information rich, requires an expert to interpret and looks like this:

![MR Output Diagram]

Compact MR + AI + Cloud Output

- Uses application-specific MR output and compares with databases, computer software analysis etc. to eliminate need for expert.
- Applications can be easily integrated into existing software.

Output looks like this:

- There **is** fentanyl in suspicious powder
- There **is no** fentanyl in suspicious powder

Image-based or spectroscopic output data must be simpler so non-experts can understand and take action
Market Opportunity & Current Customers

Marketing & Sales
- We sell direct in US, Canada, France, Germany, Switzerland
- We sell in countries such as Japan via dealers
- Market extensively at conferences and digital

Miniaturization - Growth Drivers
- Miniaturization is making equipment standard in every lab and other places
- New industry-specific applications with global market potential
- Compact MRI, Cloud, and AI is expected to create opportunities for personalized healthcare in MRI space
- Total Addressable Market is $3B and growing*

Scientific Instrumentation market was $75B per year in 2020*

Customers Include: Over 900 Units Shipped

*2020 Strategics Directions International Market Report

Almost Everything in the modern world is tested and measured for: Innovation, Health & Safety, QA/QC, and Efficient Manufacturing
Independent Board of Directors

CHAIRMAN OF THE BOARD

Martin Burian
CPA-CA, CBV, ICD.D

On several public company boards and actively seeks investments in private operating companies through Burian Investments Inc. and helps businesses looking to go public leveraging his 30 years of Canadian investment banking experience which includes senior positions at Canaccord Capital and Haywood Securities.

Werner Gartner
CPA/CMA and Technology Investor

Mr. Gartner has over 25 years executive/board experience with technology based businesses (e.g., NovAtel Inc., Hemisphere GNSS Inc., 4iiii Innovation Inc, Psyko Audio Labs Inc. & Novariant Inc.).

Dr. Michal Okoniewski
CSO & Co-Founder, Acceleware

Dr. Okoniewski is a Professor of Electrical & Computer Engineering (Schulich School of Engineering U of Calgary), Fellow of IEEE with over 350 technical publications and holding several patents. He is a world renowned expert in electromagnetics.

Dr. Rene Lenggenhager
Co-CEO bNovate Technologies SA

Dr. Lenggenhager is an experienced CEO, Group Head and General Manager with a successful career in globally leading technology companies, including at Bruker Biospin, COMET, Mettler Toledo and Siemens. He holds a PhD from ETH in Switzerland and an MBA from University of St. Gallen.

Guido Cloetens
CEO & Chairman, Elysee Development

Mr. Cloetens is the CEO and Chairman of Elysee Developments Corp. and serves as a director at Edgemont Gold Corp. He has over 25 years of capital market experience.

Sean Krakiwsky, CEO is also a Director
Thank You!

Highly educated global workforce of ~165 people
Our Employees are Shareholders!

40 PhDs | 35 MScs | 60 BScs

Headquarters are in Calgary
USA Office in Phoenix; European Offices in Strasbourg/Zurich

Matt Selinger
Investor Relations Manager
+1.415.572.8152
mselinger@firmirgroup.com